Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G reporting ownership of common stock of Inspire Medical Systems, Inc. The filing shows an aggregate beneficial ownership of 741,312.10 shares, representing 2.5% of the outstanding common stock. FMR LLC reports sole voting power of 739,599 shares and sole dispositive power of 741,312.10 shares; Abigail P. Johnson reports sole dispositive power of 741,312.10 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing control. The filing includes referenced exhibits and powers of attorney.
Citadel and related entities reported ownership stakes in Inspire Medical Systems (INSP). The joint Schedule 13G shows Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,379,861 shares representing 4.7% of outstanding common stock. Citadel Securities LLC reported 114,245 shares (0.4%), and Citadel Securities Group LP and Citadel Securities GP LLC each reported 333,181 shares (1.1%). Mr. Kenneth Griffin is reported with shared beneficial ownership of 1,713,042 shares (5.8%). The filing states holdings are as of the market open on 10/06/2025 and uses a share base of 29,574,316 shares for percentage calculations.
Richard Buchholz, Chief Financial Officer and Director of Inspire Medical Systems, Inc. (INSP), reported an insider sale on 08/29/2025 of 11,000 shares of common stock at a price of $93.39 per share. After the sale, Mr. Buchholz beneficially owned 44,867 shares (direct). The filing also discloses indirect holdings of 1,475 shares each held by his daughter and three sons. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Inspire Medical Systems (INSP) filed a Form 144 notifying a proposed sale of 11,000 common shares through RBC Capital Markets on 08/29/2025 on the NYSE, with an aggregate market value of $1,027,349.00. The filing reports 29,574,316 shares outstanding, so the proposed block represents roughly 0.04% of outstanding shares. All 11,000 shares were acquired by option exercise between 06/30/2019 and 10/09/2020, totaling the same 11,000 shares listed for sale. No securities were sold by the filer in the past three months, and the filer certifies no undisclosed material adverse information.
Inspire Medical Systems (INSP) announced that Chief Financial Officer Richard J. Buchholz has notified the company he will step down to pursue other professional opportunities. Mr. Buchholz and the company entered a Transition and Separation Agreement under which his resignation will be effective on the earlier of December 31, 2025 or the date a permanent successor CFO commences employment. He will remain principal financial and accounting officer through that date and then serve as a financial advisor through February 28, 2026 while receiving base salary and benefits.
The agreement provides for a cash payment equal to nine months of his 2025 annual base salary and up to nine months of COBRA coverage. The company has engaged a leading executive search firm to recruit a new CFO. The filing discloses customary confidentiality, non-disparagement and release provisions and incorporates the full separation agreement as Exhibit 10.1 and a press release as Exhibit 99.1.
Inspire Medical Systems CFO Richard Buchholz reported multiple acquisitions of company stock on 08/19/2025. He exercised employee stock options and purchased shares, increasing his direct holdings. The Form 4 shows exercises of options with strike prices of $71 (17,849 shares) and $42.15 (7,159 shares), plus recognition of shares withheld for tax obligations (2,649; 2,455; 276) and 113 shares from the 2018 Employee Stock Purchase Plan. After the transactions, his reported direct common stock holdings range across entries (for example, 61,247 and 58,598 shares). Certain family members are reported as indirect holders (each 1,475 shares).
Inspire Medical Systems disclosed that its Board has authorized the repurchase of up to $200.0 million of the company’s outstanding common stock. The filing indicates the board approved a buyback authorization but does not include details on timing, methods, or the pace of repurchases.
The filing also furnishes the company press release as Exhibit 99.1 and includes Inline XBRL cover page tags. No financial results, program specifics, or additional transaction terms are provided within this report.